Surrozen, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 29.46 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 515.41M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-β, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Details
| Name | Surrozen, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 44 |
| Founded | 2015 |
| Ceo | Craig Parker |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US86889P2083 |
| Cusip | 86889P208 |
| Cik | 1824893 |
| Sic | 2836 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Craig C. Parker M.B.A. | Chief Executive Officer, President and Director |
| Charles Williams | Chief Operating Officer and Corporate Secretary |
| Dr. Yang Li Ph.D. | Executive Vice President of Research |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Roeland Nusse Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Calvin Kuo M.D., Ph.D. | Co-Founder and Member of Scientific Advisor |
| Andrew Maleki | Chief Financial Officer |
| Dr. Daniel L. Chao M.D., Ph.D. | Vice President and Head of Clinical Development |
| Michael Lauw M.S.W. | Senior Vice President of Development Operations |
| Esther Jhun | Controller |
Contact
| Address | 171 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080, United States |
| Phone | 650 489 9000 |
| Website | https://www.surrozen.com |